Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II

Multiple Sclerosis Clinical Trial

Official title: Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II

Status Completed

Clinical Trial Summary

The goal of this longitudinal study is to (1) explore the association between the gut microbiota and inflammatory disease activity in early onset multiple sclerosis, (2) investigate whether/how gut microbial composition vary when patients experience a relapse, and (3) to assess whether the gut microbiota shows increased similarities between affected pairs of first-degree relatives within the same family when compared with discordant pairs of first-degree relatives.

Clinical Trial Description

Using metagenomics, as well as clinical, immunological, and radiological observations, the investigators will investigate if active relapsing-remitting multiple sclerosis patients have a more pro-inflammatory gut microbiota signature than multiple sclerosis patients with less active disease and matched healthy controls. More specifically, the investigators will investigate whether temporal variability of the gut microbiota is related to inflammatory disease activity in multiple sclerosis, whether changes in the gut microbiota are predictive of future inflammatory disease activity in multiple sclerosis, and whether gut microbiota characteristics are predictive of the disease course after 2 years. ;

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

• NCT number: NCT03797937
• Study type: Interventional
• Source: National MS Center Melsbroek
• Status: Completed
• Phase: N/A
• Start date: November 1, 2018
• Completion date: May 1, 2022